Literature DB >> 3000393

A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite.

H G Eckert, G Münscher, R Oekonomopulos, H Strecker, H Urbach, H Wissmann.   

Abstract

A radioimmunoassay (RIA) has been developed for the measurement of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)- 2-azabicyclo[3.3.0]octane-3-carboxylic acid (ramipril, Hoe 498) and its active metabolite (diacid: hydrolysis product of ramipril) in serum or plasma. Antibodies to the diacid were raised in rabbits against a lysine analogue conjugated to bovine serum albumin. A 125I-ramipril-diacid derivative was used as radioligand. Separation of the antibody-bound and free radiolabeled ligand was achieved by employing a polyethylene glycol solution. The RIA is specific for the active metabolite (diacid). Studies on specificity showed less than 0.6% cross-reactivity with intact ramipril or with dioxopiperazine metabolites. The levels for intact ramipril were obtained by prior enzymatic hydrolysis to the diacid. The sensitivity of the assay was 0.1 and 0.5 ng/ml for diacid and ramipril, respectively. Intra- and inter-assay coefficients of variation ranged from 3 to 14% at 1 to 30 ng diacid per ml. A recovery experiment yielded an average of 103%. The assay has been used to investigate the pharmacokinetic profile of both ramipril and its pharmacologically active metabolite.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3000393

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

1.  A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects.

Authors:  A D Bainbridge; R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Lack of interaction between ramipril and simvastatin.

Authors:  B H Meyer; H E Scholtz; F O Müller; H G Luus; N de la Rey; M Seibert-Grafe; H G Eckert; H Metzger
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

4.  Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency.

Authors:  H Schunkert; J Kindler; M Gassmann; W Lahn; R Irmisch; E Ritz; E R Debusmann; J O Pujadas; K M Koch; H G Sieberth
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

6.  Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study.

Authors:  B Beermann; O Nyquist; C Höglund; K A Jacobsson; U Näslund; M Jensen-Urstad
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination.

Authors:  G Ruf; S Gera; H G Luus; D Trenk; N de la Rey; K Löffler; W Schulz; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril.

Authors:  J M van Griensven; R C Schoemaker; A F Cohen; H G Luus; M Seibert-Grafe; H J Röthig
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure.

Authors:  H Berglund; O Nyquist; B Beermann; M Jensen-Urstad; E Theodorsson
Journal:  Br Heart J       Date:  1994-12

Review 10.  Clinical pharmacokinetics of ramipril.

Authors:  S Meisel; A Shamiss; T Rosenthal
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.